RNAi Roundup: Alnylam and Ribopharma Create an 800-Pound Gorilla; Intradigm Tackles Delivery; Virtual RNAi Conference | GenomeWeb

NEW YORK, July 11 - Monday's merger between short interfering RNA therapeutics firms Alnylam and Ribopharma started with friendly discussions between the management at the two companies, but was heavily influenced by venture capitalists' desire to establish a dominant presence in the market.


Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Pacific Biosciences is hosting a competition in which researchers are vying to win free sequencing for an organism with the most interesting genome.

An opinion piece appearing in Newsday likens familial DNA searches to stop-and-frisk policies.

The San people of Africa have drawn up a code of conduct for researchers, according to the Conversation.

In Nature this week: genotypes linked to hip osteoarthritis, and more.